Top Markets
Coin of the day
Scopus BioPharma Inc. Scopus BioPharma Inc.

Scopus BioPharma Inc.

SCPS
Pozycja w akcjach #41540
Scopus BioPharma Inc. is a biopharmaceutical company in the clinical... Scopus BioPharma Inc. is a biopharmaceutical company in the clinical development phase, dedicated to pioneering innovative treatments for serious diseases. Its core development programs are concentrated on immuno-oncology gene therapies designed to combat various forms of cancer. The company's offerings include the Duet Platform, which incorporates CpG signal transducer and activator of transcription 3 (STAT3) inhibitors. Another significant product is MRI-1867, a cleverly engineered, orally administered, dual-action hybrid small molecule. MRI-1867 functions as an inverse agonist of the endocannabinoid system's cannabinoid receptor 1 (CB1) and additionally acts as an inhibitor of inducible nitric oxide synthase (iNOS). To advance its key development efforts and other programs, Scopus BioPharma has established strategic collaborations with prominent organizations such as the City of Hope, the National Institutes of Health Program, and The Hebrew University of Jerusalem. Established in 2017, the company was originally named Project18 Inc. before officially rebranding to Scopus BioPharma Inc. in December of that year. Its corporate headquarters are located in New York, New York.
Cena akcji
$0.0004
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$16.83K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
33.33%
Kraj
US
Handel Scopus BioPharma Inc. (SCPS)

Kategoria

EPS dla Scopus BioPharma Inc. (SCPS)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Scopus BioPharma Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Scopus BioPharma Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów